A novel thiol-saccharide mucolytic for the treatment of muco-obstructive lung diseases.

"Conflict of interest: W. Raymond is co-inventor on a patent application (PCT/US19/50475) that describes MUC-031 and related structures. I. Gitlin reports support for the present work from NIH/NHLBI (P01HL128191), and is also co-inventor on a patent application (PCT/US19/50475) that describes MUC-031 and related structures, and a shareholder in Aer Therapeutics, an early-stage company that has licensed MUC-031 technology. A. Charbit reports support for the present work from NIH/NHLBI (P01HL128191). X. Orain reports support for the present work from NIH/NHLBI (P01HL128191). A.W. Scheffler reports the following support for the present manuscript: statistical consulting coordinated via UCSF Clinical and Translational Science Institute, funds provided by NIH P01HL128191. S.Y. Graeber reports grants from Mukoviszidose e.V. (German CF Foundation), Vertex Pharmaceuticals Incorporated, German Ministry for Education and Research (BMBF) and Deutsche Forschungsgemeinschaft (DFG, German Research Foundation), and lecture honoraria from and advisory board participation for Chiesi GmbH and Vertex Pharmaceuticals Incorporated, outside the submitted work. A-M. Healy reports support for the present manuscript from NIH/NHLBI (P01HL128191, R01HL080414) and Science Foundation Ireland (SFI) (grants 12/RC/2275, 12/RC/2275_P2, 12/RC/2278), and is a shareholder in Aer Therapeutics, an early-stage company that has licensed MUC-031 technology. S. Oscarson reports support for the present manuscript from NIH/NHLBI (P01HL128191, R01HL080414), and is also co-inventor on a patent application (PCT/US19/50475) that describes MUC-031 and related structures, and a shareholder in Aer Therapeutics, an early-stage company that has licensed MUC-031 technology. J.V. Fahy reports grants from NIH/NHLBI, consulting fees from Suzhou Connect Biopharmaceuticals, Ltd, stock options/grants from Suzhou Connect Biopharmaceuticals, Ltd and Aer Therapeutics, outside the submitted work; and is also the inventor of patents PCT/US2014/028656 and PCT/US19/50475, which describe thiol-modified saccharides as drugs to treat mucus associated lung diseases. M.A. Mall reports support for the present manuscript from National Heart, Lung and Blood Institute (P01HL128191), German Ministry for Education and Research (BMBF) (82DZL009B1), Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) (CRC 1449 – 431232613 (A01, C04 and Z02)), and also reports, outside the present work, consulting fees from Boehringer Ingelheim, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, Santhera, Sterna Biologicals, Enterprise Therapeutics, Antabio and Abbvie, lecture honoraria from Boehringer Ingelheim, Arrowhead Pharmaceuticals and Vertex Pharmaceuticals, travel support from Boehringer Ingelheim and Vertex Pharmaceuticals, advisory board participation with Boehringer Ingelheim, Arrowhead Pharmaceuticals, Vertex Pharmaceuticals, Santhera, Enterprise Therapeutics, Antabio, Kither Biotech, Abbvie and Pari; and was a member of the board (2012–2020) and vice-president (2018–2020) of European Cystic Fibrosis Society. All other authors have nothing to disclose."

"Support statement: This study was supported by P01HL128191 and R01HL080414 from the National Heart, Lung, and Blood Institute, the German Research Foundation (CRC 1449–431232613 A01, C04 and Z02) and the German Federal Ministry of Education and Research (82DZL009B1). S.Y. Graeber is a participant of the BIH-Charité Clinician Scientist Program funded by the Charité – Universitätsmedizin Berlin and the BIH. Funding information for this article has been deposited with the Crossref Funder Registry."